* Evolent Health Inc EVH.N EVH is expected to show a
rise in
quarterly revenue when it reports results on May 9 for the
period ending January 1 0001
* The Arlington Virginia-based company is expected to
report a
40.5% increase in revenue to $600.818 million from $427.69
million a year ago, according to the mean estimate from 14
analysts, based on LSEG data.The company's guidance on February
22 2024, for the period ended March 31, was for revenue between
$595.00 million and $610.00 million.
* LSEG's mean analyst estimate for Evolent Health Inc is
for
earnings of 24 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Evolent
Health
Inc is $44.00, above its last closing price of $27.61.
The company's guidance on February 22 2024 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between USD595 million and USD58 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.17 0.15 0.23 Beat 54.5
Sep. 30 2023 0.09 0.07 0.30 Beat 337.5
Jun. 30 2023 0.12 0.11 0.14 Beat 24
Mar. 31 2023 0.21 0.20 0.21 Beat 3.7
Dec. 0.20 0.16 0.10 Missed -39.1
31 2022
Sep. 30 2022 0.13 0.12 0.59 Beat 397.6
Jan. 1 0001 0.05 0.05 0.10 Beat 105.9
Mar. 31 2022 0.00 0.00 0.12 Beat 6,100
This summary was machine generated May 7 at 23:25 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)